Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro ...

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...

Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase access for patients without insurance coverage for the highly popular ...

Eli Lilly (NYSE: LLY) currently leads the weight loss market thanks to Zepbound. Given that analysts project this area will gain significant traction in the coming years, that may provide a ...

Discover how Eli Lilly is increasing medical weight loss access in Indiana through Zepbound vials. Learn how this Indy innovation supports long-term health. By combining lower pricing, direct-to ...

Clinical trial results for retatrutide, Eli Lilly’s next weight loss drug, showed far more weight loss than other blockbuster ...

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of ...